Natera (NASDAQ:NTRA) Insider Sells $1,401,003.63 in Stock

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 3,419 shares of the business’s stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $409.77, for a total transaction of $1,401,003.63. Following the sale, the insider owned 101,323 shares in the company, valued at $41,519,125.71. This trade represents a 3.26% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Solomon Moshkevich also recently made the following trade(s):

• On Wednesday, October 28th, Solomon Moshkevich sold 1,162 shares of Natera stock. The shares were sold at an average price of $426.34, for a total value of $495,407.08.
• On Tuesday, October 27th, Solomon Moshkevich sold 1,010 shares of Natera stock. The shares were sold at an average price of $406.00, for a total value of $410,060.00.
• On Thursday, October 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The shares were sold at an average price of $414.22, for a total transaction of $1,242,660.00.
• On Wednesday, September 2nd, Solomon Moshkevich sold 15,160 shares of Natera stock. The shares were sold at an average price of $326.89, for a total transaction of $4,955,652.40.
• On Tuesday, September 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The shares were sold at an average price of $320.73, for a total transaction of $962,190.00.

Natera Price Performance

NTRA stock traded up $2.40 during midday trading on Wednesday, hitting $391.03. 2,799,993 shares of the company’s stock were exchanged, compared to its average volume of 1,672,252. The firm has a 50 day moving average price of $380.30 and a 200-day moving average price of $268.64. Natera, Inc. has a 12-month low of $181.00 and a 12-month high of $437.41.

Natera (NASDAQ:NTRA) last issued its quarterly earnings results on Thursday, August 6th. The medical research company reported ($0.47) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.02. The business had revenue of $752.75 million during the quarter, compared to the consensus estimate of $661.24 million. Natera had a negative return on equity of 11.38% and a negative net margin of 7.11%. The business’s quarterly revenue was up 37.7% on a year-over-year basis. During the same period in the previous year, the business earned ($0.74) EPS. Analysts predict that Natera, Inc. will post -1.14 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. BlackRock Inc. bought a new stake in Natera during the 2nd quarter valued at $2,962,770,000. Bank of America Corp DE purchased a new stake in Natera during the 2nd quarter valued at about $199,960,000. Legal & General Group Plc purchased a new stake in Natera in the second quarter worth approximately $150,143,000. Bank of New York Mellon Corp purchased a new position in Natera during the second quarter valued at $149,278,000. Finally, Avala Global LP bought a new position in shares of Natera in the second quarter worth about $124,867,000. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Analysts Set New Price Targets

NTRA has been the topic of a number of research analyst reports. Barclays raised their target price on shares of Natera from $340.00 to $475.00 and gave the company an “overweight” rating in a research note on Wednesday, October 7th. Guggenheim raised their price objective on shares of Natera from $360.00 to $475.00 and gave the stock a “buy” rating in a research note on Thursday, October 1st. Leerink Partners set a $330.00 target price on shares of Natera in a research note on Friday, August 7th. Royal Bank Of Canada raised their price objective on Natera from $350.00 to $460.00 and gave the stock an “outperform” rating in a research report on Friday, September 25th. Finally, Zacks Research lowered Natera from a “hold” rating to a “strong sell” rating in a research note on Friday, October 16th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, two have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $394.31.

Natera News Summary

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Medicare coverage for Signatera in HCC could improve patient access and support adoption of Natera’s cancer-monitoring tests. The coverage milestone adds to the commercial opportunity for its oncology business. Natera Medicare coverage for Signatera in HCC
• Positive Sentiment: New ESMO oncology evidence was described as broadening the case for Natera’s cancer-testing portfolio, potentially reinforcing the longer-term growth story. ESMO data broaden Natera’s oncology case
• Neutral Sentiment: Natera was expected to report earnings on November 5, making results and management’s outlook a near-term catalyst; the preview article did not provide reported results. Natera earnings preview
• Neutral Sentiment: The reported analyst consensus price target was $394.31, close to the share price cited in the provided market background, suggesting limited implied upside from that target alone. Natera consensus target price
• Neutral Sentiment: CFO Michael Brophy sold 1,178 shares under a pre-arranged Rule 10b5-1 plan and retained 48,480 shares. The scheduled nature and relatively small size of the sale may temper its significance as a signal about management’s outlook. CFO share sale report

Natera Company Profile

Natera, Inc is a diagnostics company that develops and commercializes molecular testing services designed to provide personalized genetic and genomic information. Its tests are used across reproductive health, oncology and organ transplantation, with the company combining next-generation sequencing and bioinformatics to analyze DNA and monitor disease-related signals.

In reproductive health, Natera offers Panorama noninvasive prenatal screening, Horizon carrier screening and Vistara single-gene disorder screening.